ClinicalTrials.gg
Not yet recruitingNCT07544043TARGET-CAUpdated Nov 12, 2026

Transradial vs Transfemoral Group-Randomized Efficacy and Safety Trial for Cerebral Angiography

An interventional study of Cerebral Angiography via the Transfemoral Approach and Cerebral Angiography via the Transradial Approach in Cerebrovascular Disease, sponsored by Gansu Provincial Maternal and Child Health Care Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Gansu Provincial Maternal and Child Health Care Hospital · Not applicable, Interventional, and Other

How we know

Updated Nov 12, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,520
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will compare the efficacy and safety of the transradial approach versus the transfemoral approach for performing full cerebral angiography. Participants will undergo cerebral angiography via one of the two approaches and will be followed up during and after the procedure. The primary endpoint of this study is to evaluate the success rate of completing full cerebral angiography (including superselective catheterization of bilateral common carotid arteries, subclavian arteries near the vertebral artery origin, and the aortic arch) via the transradial approach versus the transfemoral approach. During the study, the medical team will also document procedural details, incidence of complications, patient comfort, and related costs to comprehensively evaluate the clinical performance differences between the two approaches.

Read the detailed description

With the increasing global prevalence of cerebrovascular diseases and the growing demand for precise treatment, accurate diagnosis has become crucial. As the "gold standard" for diagnosing cerebrovascular diseases, digital subtraction angiography (DSA) is being increasingly utilized and required in clinical practice. For a long time, the transfemoral approach (TFA) has been the standard access route for clinical neurointervention due to its anatomical advantages, such as straight vascular pathways, strong instrument support, and ease of operation. However, as clinical cases accumulate, the limitations of TFA have become increasingly evident: the incidence of puncture site-related vascular complications (e.g., hematoma, pseudoaneurysm, retroperitoneal hemorrhage) is relatively high, and patients require strict bed rest and immobilization postoperatively. This not only leads to suboptimal perioperative comfort for patients but also significantly increases clinical nursing burdens and healthcare costs.

In the field of coronary intervention, multiple large-scale randomized controlled trials (e.g., the RIVAL study) have established the superiority of the transradial approach (TRA) in reducing bleeding complications and all-cause mortality. Inspired by this, TRA has gradually been applied in the field of neurointervention. The main advantages of TRA lie in the superficial location of the radial artery, which facilitates compression hemostasis, and the dual blood supply from the ulnar artery as collateral circulation, greatly reducing the risk of severe puncture site complications. Additionally, patients do not require bed rest postoperatively, significantly improving perioperative comfort and shortening perioperative time.

However, despite TRA becoming the first-line choice in cardiac intervention, its application in cerebrovascular angiography still faces unique challenges. Since cerebral vessels originate from the aortic arch, reaching the target vessels (especially the left carotid artery) from the radial artery involves navigating more tortuous anatomical pathways (such as the aortic arch and the turn of the innominate artery), which differs fundamentally from the anatomical pathways in coronary intervention. Therefore, conclusions from coronary intervention studies cannot be directly applied to the field of neurointervention. Currently, comparative studies of TRA and TFA in cerebrovascular angiography are mostly limited to single-center, retrospective analyses, and there remains a lack of high-quality prospective randomized controlled trials (RCTs) to provide high-level evidence-based medical data for evaluating their operational success rates, radiation exposure times, and long-term safety under different anatomical variations.

Based on this, this study aims to objectively evaluate the effectiveness and safety of the two approaches by comparing clinical data from TRA and TFA for full cerebrovascular angiography, thereby providing scientific evidence for clinical physicians to choose the optimal surgical pathway.

02

Conditions studied

  • Cerebrovascular Disease
03

In context

Cerebrovascular Disorders

450 studies on the registry are indexed under Cerebrovascular Disorders; 126 are open to participants now.

This study's planned enrollment of 3,520 is above the median of 100 across 274 interventional studies indexed under Cerebrovascular Disorders.

Browse Cerebrovascular Disorders studies →

Lead sponsor

Gansu Provincial Maternal and Child Health Care Hospital is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18 years;
  2. Patients requiring full cerebrovascular angiography;
  3. Objective evidence indicates the patient is suitable for transfemoral or transradial cerebrovascular angiography, with upper limb vascular ultrasound 4.showing a radial artery internal diameter ≥ 1.5 mm;

5. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Positive right Allen's test/Barbeau test; femoral artery occlusion (for the TFA group);
  2. Local infection or trauma at the puncture site;
  3. Coagulation abnormalities: > 1.5 or count \< 50 × 10⁹/L;
  4. Presence of access vessel disease or anatomical variation deemed potentially hazardous to the subject, such as aortic arch interruption, subclavian artery occlusion, or aortic dissection;
  5. Pregnancy;
  6. Planned or recent (within the past 2 weeks) major surgery or severe trauma;
  7. Expected survival less than 5 years;
  8. Severe cardiac, hepatic, renal, or other organ dysfunction;
  9. to contrast agents used in cerebrovascular angiography;
  10. Clinical Dementia Rating ≥ 2
  11. Inability to comply with follow-up.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,520 participants (estimated)

Study arms

  • Experimental
    Transradial Approach

    Following successful radial artery puncture, a 5F radial sheath was inserted. After sheath placement, an intra-arterial cocktail was administered via the sheath, consisting of nitroglycerin 200 μg, verapamil 2.5 mg, and a heparinized saline flush (30-40 U/kg). Standard full cerebral angiography was then performed. Upon completion of the procedure, hemostasis was achieved using a dedicated radial artery compression device. The pressure was gradually released and completely removed 3-6 hours postoperatively.

    Procedure: Cerebral Angiography via the Transradial Approach

  • Active comparator
    Transfemoral Approach

    Following successful femoral artery puncture, a 5F femoral sheath was inserted. After sheath placement, a heparinized saline flush was administered intra-arterially. Standard full cerebral angiography was then performed. Upon completion of the procedure, hemostasis was initially achieved via manual compression for 15-20 minutes, followed by the application of a pressure dressing which was maintained for 6-24 hours.

    Procedure: Cerebral Angiography via the Transfemoral Approach

Interventions

  • ProcedureCerebral Angiography via the Transfemoral Approach

    Following successful radial artery puncture, a 5F radial sheath was inserted. After sheath placement, an intra-arterial cocktail was administered via the sheath, consisting of nitroglycerin 200 μg, verapamil 2.5 mg, and a heparinized saline flush (30-40 U/kg). Standard full cerebral angiography was then performed. Upon completion of the procedure, hemostasis was achieved using a dedicated radial artery compression device. The pressure was gradually released and completely removed 3-6 hours postoperatively.

  • ProcedureCerebral Angiography via the Transradial Approach

    Following successful radial artery puncture, a 5F radial sheath was inserted. After sheath placement, an intra-arterial cocktail was administered via the sheath, consisting of nitroglycerin 200 μg, verapamil 2.5 mg, and a heparinized saline flush (30-40 U/kg). Standard full cerebral angiography was then performed. Upon completion of the procedure, hemostasis was achieved using a dedicated radial artery compression device. The pressure was gradually released and completely removed 3-6 hours postoperatively.

06

What researchers measure

Primary outcomes

  1. The completion of cerebral angiography

    The primary endpoint of this study is to evaluate the success rate of completing full cerebral angiography (including superselective catheterization of bilateral common carotid arteries, subclavian arteries near the vertebral artery origin, and the aortic arch) via the transradial approach versus the transfemoral approach

    Time frame: 30 minutes

Secondary outcomes

  1. The incidence of treatment-emergent adverse events (safety and tolerability) associated with TRA compared to TFA in cerebrovascular angiography

    To evaluate the safety of TRA versus TFA in full cerebrovascular angiography by comparing complication rates (e.g., access-site hematoma, pseudoaneurysm, retroperitoneal hemorrhage), procedural duration, fluoroscopy time, and required bed rest duration

    Time frame: 1 to 30 days

  2. Comparative Cost-effectiveness of TRA versus TFA in Cerebrovascular Angiography

    To assess the cost-effectiveness of TRA versus TFA in full cerebrovascular angiography by analyzing direct and indirect costs associated with the procedure and the perioperative period.

    Time frame: 1 to 30 days

  3. Visual Analogue Scale Score for Pain of TRA versus TFA in Cerebrovascular Angiography

    To compare patient-reported pain levels between transradial access (TRA) and transfemoral access (TFA) in full cerebrovascular angiography. Pain will be assessed using the Visual Analogue Scale (VAS), which ranges from 0 to 10, where higher scores indicate worse pain (i.e., a worse outcome).

    Time frame: 1 to 24 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 96 non-industry interventional studies with no phase under Cerebrovascular Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 68. This study's planned 12 months is below that.

Counting every sponsor, half of 111 studies reached it within 30 months; a quarter within 14 and three quarters within 68.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start May 2026 → Dec 2026, primary completion May 2027 → Dec 2027 and completion May 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2026
First posted
Apr 22, 2026
StartEst.
Dec 1, 2026was May 2026
Primary completionEst.
Dec 1, 2027was May 2027
CompletionEst.
Dec 1, 2027was May 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 1, 2026→Dec 1, 2026
Nov 12, 2026
Primary completion
May 1, 2027→Dec 1, 2027
Nov 12, 2026
Study completion
May 1, 2027→Dec 1, 2027
Nov 12, 2026
Enrollment
2473→3520
Nov 12, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion added
What changed in the criteria
Inclusion criteria
  • ChangedBefore 5.Modified Rankin Scale (mRS) score ≤ 2 points; 6.Signed informed consent form.Now 5. Signed informed consent form.
Exclusion criteria
  • AddedClinical Dementia Rating ≥ 2
Nov 12, 2026
Secondary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameThe incidence of treatment-emergent adverse events (safety and tolerability) associated with TRA compared to TFA in cerebrovascular angiography1 to 7 days → 1 to 30 days
  • Time frameComparative Cost-effectiveness of TRA versus TFA in Cerebrovascular Angiography1 to 7 days → 1 to 30 days
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date May 1, 2026→Dec 1, 2026
    Primary completion May 1, 2027→Dec 1, 2027
    Study completion May 1, 2027→Dec 1, 2027
    Enrollment 2473→3520
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore 5.Modified Rankin Scale (mRS) score ≤ 2 points; 6.Signed informed consent form.Now 5. Signed informed consent form.
    Exclusion criteria
    • AddedClinical Dementia Rating ≥ 2
    Secondary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameThe incidence of treatment-emergent adverse events (safety and tolerability) associated with TRA compared to TFA in cerebrovascular angiography1 to 7 days → 1 to 30 days
    • Time frameComparative Cost-effectiveness of TRA versus TFA in Cerebrovascular Angiography1 to 7 days → 1 to 30 days
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07544043
Lead sponsor
Gansu Provincial Maternal and Child Health Care Hospital
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Yin Rong
Contact
yin_rong_@163.com
+8613919930466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion